Pages

▼
Monday, February 27, 2023

Ixekizumab (Taltz) Starts a Phase-II? Trial In Honeymooners

›
Ixekizumab, sold under the trade name Taltz, blocks a specific part of the immune system called Interleukin 17 (IL-17).  It has been approve...
Thursday, February 9, 2023

OPT101 Starts A Phase-I Trial in Adults with Established T1D

›
OPT101 is a peptide derived from mouse CD154.  What does that mean?  A peptide is a small part of a protein.  CD154 is a protein found on so...
1 comment:
Monday, December 26, 2022

Youtube Video Describing How JDRF Makes Funding Decisions

›
If you care about research aimed at curing type-1 diabetes, then you should care about JDRF's research funding.  Year after year, they f...
Thursday, December 15, 2022

ADSCC Starts Phase-I Clinical Trial of Extracorporeal Photopheresis (Opera)

›
This is a phase-I, 10 person trial which started in September 2022, and is expected to finish in January 2024.  This trial is for adults (18...
Saturday, December 3, 2022

The FDA Approves Teplizumab Under The Name TZIELD™ (teplizumab-mzwv)

›
On 17-Nov-2022, The USA FDA approved Teplizumab.  This is the first drug ever approved in the United States which changes the course of Type...
Wednesday, November 16, 2022

Results from MultiPepT1De (Multi Peptide Vaccine) by Powrie at King’s College London

›
This is the most recent result from a long line of research led by Colin Dayan and Mark Peakman, at Cardiff University and King's Colleg...
Sunday, October 16, 2022

JDRF Funding for a Cure 2022

›
In the US, we are in the "Walking Season" when JDRF (Juvenile Diabetes Research Foundation) asks us to walk to raise money for a ...